APPRAISE Study- Assessment of Primary Prevention Patients Receiving An ICD
Brief description of study
The value of Antitachycardia Pacing (ATP) in primary prevention patients who receive implantable cardioverter defibrilator (ICDs) is uncertain. The purpose of this study is to better understand the value of ATP in primary prevention patients. This study is to see if certain programing will reduce the number of shocks received and improve survival rate.
Patients that participate in the study, your device will be set to either: Deliver ATP first and only deliver shock if needed or Deliver only shock treatments (no ATP treatment). Participants are patients that have already received an implantable cardioverter defibrillator (ICD) which is already approved for use by the FDA, and includes patients who meet the guidelines for ICD therapy for primary prevention patients.
ICD’s may include a feature which allows for the device to deliver fast pacing signals which may help your heart return to a normal speed. This is called Antitachycardia pacing (ATP). Sometimes, however, these pacing signals may be given when not needed (inappropriate ATP) or can make the heart beat even faster, which can lead to a shock from the device. ATP can stop some VT, but does not stop VF. ATP is not usually felt. ATP can be turned on or off by your doctor within your device.
The number of patients expected to participate in the study will be approximately 2,600 at up to 200 study centers in the United States, Europe, Canada and Japan.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
pacemaker,cardiac,defibrillator
-
Age: Between 21 Years - 99 Years
-
Gender: All
Updated on
09 Mar 2024.
Study ID: 829807
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
